Last reviewed 2026-04-23 · How we verify

KX2-391 Ointment 1%

KX2-391 is a Src kinase inhibitor that reduces skin inflammation and keratinocyte proliferation in atopic dermatitis.

KX2-391 is a Src kinase inhibitor that reduces skin inflammation and keratinocyte proliferation in atopic dermatitis. Used for Atopic dermatitis.

At a glance

Mechanism of action

KX2-391 selectively inhibits Src family kinases, which are involved in inflammatory signaling pathways and keratinocyte activation in atopic dermatitis. By blocking these kinases, the drug reduces inflammatory cytokine production and abnormal skin cell proliferation, leading to improved skin barrier function and reduced itching and inflammation.

Approved indications

• Atopic dermatitis

Common side effects

• Application site irritation
• Pruritus
• Erythema

Key clinical trials

• Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp (PHASE2)
• A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (PHASE3)
• A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004) (PHASE3)
• Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis (PHASE1)
• Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• KX2-391 Ointment 1% CI brief — competitive landscape report
• KX2-391 Ointment 1% updates RSS · CI watch RSS
• Almirall, S.A. portfolio CI